New therapeutic strategies for Alzheimer’s disease

[1] Aducanumab. https://www.alzforum.org/therapeutics/aducanumab (03.03.2020) Aducanumab https://www.alzforum.org/therapeutics/aducanumab (03.03.2020) Search in Google Scholar

[2] Alam J., Blackburn K., Patrick D.: Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis., 2017; 4: 273–278 AlamJ. BlackburnK. PatrickD. Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer’s disease J. Prev. Alzheimers Dis. 2017 4 273 278 Search in Google Scholar

[3] Amirrad F., Bousoik E., Shamloo K., Al-Shiyab H., Nguyen V.H., Montazeri Aliabadi H.: Alzheimer’s disease: Dawn of a new era? J. Pharm. Pharm. Sci., 2017; 20: 184–225 AmirradF. BousoikE. ShamlooK. Al-ShiyabH. NguyenV.H. Montazeri AliabadiH. Alzheimer’s disease: Dawn of a new era? J. Pharm. Pharm. Sci. 2017 20 184 225 10.18433/J3VS8P28719360 Search in Google Scholar

[4] Arndt J.W., Qian F., Smith B.A., Quan C., Kilambi K.P., Bush M.W., Walz T., Pepinsky R.B., Bussière T., Hamann S., Cameron T.O., Weinreb P.H.: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep., 2018; 8: 6412 ArndtJ.W. QianF. SmithB.A. QuanC. KilambiK.P. BushM.W. WalzT. PepinskyR.B. BussièreT. HamannS. CameronT.O. WeinrebP.H. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β Sci. Rep. 2018 8 6412 10.1038/s41598-018-24501-0591312729686315 Search in Google Scholar

[5] Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimer’s disease. https://www.prnewswire.com/news-releases/axon-announces-positive-results-from-phase-ii-adamant-trial-for-aadvac1-in-alzheimers-disease-300914509.html (03.03.2020) Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimer’s disease https://www.prnewswire.com/news-releases/axon-announces-positive-results-from-phase-ii-adamant-trial-for-aadvac1-in-alzheimers-disease-300914509.html (03.03.2020) Search in Google Scholar

[6] Bachstetter A.D., Xing B., de Almeida L., Dimayuga E.R., Watterson D.M., Van Eldik L.J.: Microglial p38α MAPK is a key regulator of pro-inflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J. Neuroinflammation, 2011; 8: 79 BachstetterA.D. XingB. de AlmeidaL. DimayugaE.R. WattersonD.M. Van EldikL.J. Microglial p38α MAPK is a key regulator of pro-inflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ) J. Neuroinflammation 2011 8 79 10.1186/1742-2094-8-79314250521733175 Search in Google Scholar

[7] Bakota L., Brandt R.: Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs, 2016; 76: 301–313 BakotaL. BrandtR. Tau biology and tau-directed therapies for Alzheimer’s disease Drugs 2016 76 301 313 10.1007/s40265-015-0529-0475760526729186 Search in Google Scholar

[8] Baranowska U., Wiśniewska R.J.: Receptor nikotynowy α7-nACh i jego znaczenie w funkcjonowaniu pamięci oraz wybranych chorobach ośrodkowego układu nerwowego. Postępy Hig. Med. Dośw., 2017; 71: 633–648 BaranowskaU. WiśniewskaR.J. Receptor nikotynowy α7-nACh i jego znaczenie w funkcjonowaniu pamięci oraz wybranych chorobach ośrodkowego układu nerwowego Postępy Hig. Med. Dośw. 2017 71 633 648 Search in Google Scholar

[9] Bearer E.L., Wu C.: Herpes simplex virus, Alzheimer’s disease and a possible role for Rab GTPases. Front. Cell Dev. Biol., 2019; 7: 134 BearerE.L. WuC. Herpes simplex virus, Alzheimer’s disease and a possible role for Rab GTPases Front. Cell Dev. Biol. 2019 7 134 10.3389/fcell.2019.00134669263431448273 Search in Google Scholar

[10] Boese A.C., Hamblin M.H., Lee J.P.: Neural stem cell therapy for neurovascular injury in Alzheimer’s disease. Exp. Neurol., 2020; 324: 113112 BoeseA.C. HamblinM.H. LeeJ.P. Neural stem cell therapy for neurovascular injury in Alzheimer’s disease Exp. Neurol. 2020 324 113112 10.1016/j.expneurol.2019.11311231730762 Search in Google Scholar

[11] Buee L.: Dementia therapy targeting tau. Adv. Exp. Med. Biol., 2019; 1184: 407–416 BueeL. Dementia therapy targeting tau Adv. Exp. Med. Biol. 2019 1184 407 416 10.1007/978-981-32-9358-8_3032096053 Search in Google Scholar

[12] Bursavich M.G., Harrison B.A., Blain J.F.: Gamma secretase modulators: New Alzheimer’s drugs on the horizon? J. Med. Chem., 2016; 59: 7389–7409 BursavichM.G. HarrisonB.A. BlainJ.F. Gamma secretase modulators: New Alzheimer’s drugs on the horizon? J. Med. Chem. 2016 59 7389 7409 10.1021/acs.jmedchem.5b0196027007185 Search in Google Scholar

[13] Caraci F., Leggio G.M., Salomone S., Drago F.: New drugs in psychiatry: Focus on new pharmacological targets. F1000Res., 2017; 6: 397 CaraciF. LeggioG.M. SalomoneS. DragoF. New drugs in psychiatry: Focus on new pharmacological targets F1000Res. 2017 6 397 10.12688/f1000research.10233.1537342028408985 Search in Google Scholar

[14] Cebers G., Alexander R.C., Haeberlein S.B., Han D., Goldwater R., Ereshefsky L., Olsson T., Ye N., Rosen L., Russell M., Maltby J., Eketjäll S., Kugler A.R.: AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 1039–1053 CebersG. AlexanderR.C. HaeberleinS.B. HanD. GoldwaterR. EreshefskyL. OlssonT. YeN. RosenL. RussellM. MaltbyJ. EketjällS. KuglerA.R. AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease J. Alzheimers Dis. 2017 55 1039 1053 10.3233/JAD-16070127767991 Search in Google Scholar

[15] Crenezumab. https://www.alzforum.org/therapeutics/crenezumab (03.03.2020) Crenezumab https://www.alzforum.org/therapeutics/crenezumab (03.03.2020) Search in Google Scholar

[16] Cummings J., Lee G., Ritter A., Sabbagh M., Zhong K.: Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement., 2019; 5: 272–293 CummingsJ. LeeG. RitterA. SabbaghM. ZhongK. Alzheimer’s disease drug development pipeline: 2019 Alzheimers Dement. 2019 5 272 293 10.1016/j.trci.2019.05.008661724831334330 Search in Google Scholar

[17] Cummings J.L., Tong G., Ballard C.: Treatment combinations for Alzheimer’s disease: Current and future pharmacotherapy options. J. Alzheimers Dis., 2019; 67: 779–794 CummingsJ.L. TongG. BallardC. Treatment combinations for Alzheimer’s disease: Current and future pharmacotherapy options J. Alzheimers Dis. 2019 67 779 794 10.3233/JAD-180766639856230689575 Search in Google Scholar

[18] Degterev A., Ofengeim D., Yuan J.: Targeting RIPK1 for the treatment of human diseases. Proc. Natl. Acad. Sci. USA, 2019; 116: 9714– 9722 DegterevA. OfengeimD. YuanJ. Targeting RIPK1 for the treatment of human diseases Proc. Natl. Acad. Sci. USA 2019 116 9714 9722 10.1073/pnas.1901179116652553731048504 Search in Google Scholar

[19] DeVos S.L., Miller R.L., Schoch K.M., Holmes B.B., Kebodeaux C.S., Wegener A.J., Chen G., Shen T., Tran H., Nichols B., Zanardi T.A., Kordasiewicz H.B., Swayze E.E., Bennett C.F., Diamond M.I. i wsp.: Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med., 2017; 9: eaag0481 DeVosS.L. MillerR.L. SchochK.M. HolmesB.B. KebodeauxC.S. WegenerA.J. ChenG. ShenT. TranH. NicholsB. ZanardiT.A. KordasiewiczH.B. SwayzeE.E. BennettC.F. DiamondM.I. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy Sci. Transl. Med. 2017 9 eaag0481 10.1126/scitranslmed.aag0481579230028123067 Search in Google Scholar

[20] Dominy S.S., Lynch C., Ermini F., Benedyk M., Marczyk A., Konradi A., Nguyen M., Haditsch U., Raha D., Griffin C., Holsinger L.J., Arastu-Kapur S., Kaba S., Lee A., Ryder M.I. i wsp.: Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv., 2019; 5: eaau3333 DominyS.S. LynchC. ErminiF. BenedykM. MarczykA. KonradiA. NguyenM. HaditschU. RahaD. GriffinC. HolsingerL.J. Arastu-KapurS. KabaS. LeeA. RyderM.I. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors Sci. Adv. 2019 5 eaau3333 10.1126/sciadv.aau3333635774230746447 Search in Google Scholar

[21] Dong Y., Li X., Cheng J., Hou L.: Drug development for Alzheimer’s disease: Microglia induced neuroinflammation as a target? Int. J. Mol. Sci., 2019; 20: 558 DongY. LiX. ChengJ. HouL. Drug development for Alzheimer’s disease: Microglia induced neuroinflammation as a target? Int. J. Mol. Sci. 2019 20 558 10.3390/ijms20030558638686130696107 Search in Google Scholar

[22] Egan M.F., Kost J., Voss T., Mukai Y., Aisen P.S., Cummings J.L., Tariot P.N., Vellas B., van Dyck C.H., Boada M., Zhang Y., Li W., Furtek C., Mahoney E., Harper Mozley L. i wsp.: Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med., 2019; 380: 1408–1420 EganM.F. KostJ. VossT. MukaiY. AisenP.S. CummingsJ.L. TariotP.N. VellasB. van DyckC.H. BoadaM. ZhangY. LiW. FurtekC. MahoneyE. Harper MozleyL. Randomized trial of verubecestat for prodromal Alzheimer’s disease N. Engl. J. Med. 2019 380 1408 1420 10.1056/NEJMoa1812840677607830970186 Search in Google Scholar

[23] Elayta. https://www.alzforum.org/therapeutics/elayta (03.03.2020) Elayta https://www.alzforum.org/therapeutics/elayta (03.03.2020) Search in Google Scholar

[24] Elenbecestat. https://www.alzforum.org/therapeutics/elenbecestat (03.03.2020) Elenbecestat https://www.alzforum.org/therapeutics/elenbecestat (03.03.2020) Search in Google Scholar

[25] Farlow M.R., Andreasen N., Riviere M.E., Vostiar I., Vitaliti A., Sovago J., Caputo A., Winblad B., Graf A.: Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease. Alzheimers Res. Ther., 2015; 7: 23 FarlowM.R. AndreasenN. RiviereM.E. VostiarI. VitalitiA. SovagoJ. CaputoA. WinbladB. GrafA. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease Alzheimers Res. Ther. 2015 7 23 10.1186/s13195-015-0108-3441046025918556 Search in Google Scholar

[26] Femminella G.D., Frangou E., Love S.B., Busza G., Holmes C., Ritchie C., Lawrence R., McFarlane B., Tadros G., Ridha B.H., Bannister C., Walker Z., Archer H., Coulthard E., Underwood B.R. i wsp.: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: Study protocol for a randomised controlled trial (ELAD study). Trials, 2019; 20: 191 FemminellaG.D. FrangouE. LoveS.B. BuszaG. HolmesC. RitchieC. LawrenceR. McFarlaneB. TadrosG. RidhaB.H. BannisterC. WalkerZ. ArcherH. CoulthardE. UnderwoodB.R. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: Study protocol for a randomised controlled trial (ELAD study) Trials 2019 20 191 10.1186/s13063-019-3259-x644821630944040 Search in Google Scholar

[27] Gantenerumab. https://www.alzforum.org/therapeutics/gantenerumab (03.03.2020) Gantenerumab https://www.alzforum.org/therapeutics/gantenerumab (03.03.2020) Search in Google Scholar

[28] Gaweł M., Potulska-Chromik A.: Choroby neurodegeneracyjne: Choroba Alzheimera i Parkinsona. Postępy Nauk Med., 2015; 7: 468–476 GawełM. Potulska-ChromikA. Choroby neurodegeneracyjne: Choroba Alzheimera i Parkinsona Postępy Nauk Med. 2015 7 468 476 Search in Google Scholar

[29] Ge M., Zhang Y., Hao Q., Zhao Y., Dong B.: Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta-analysis. Brain Behav., 2018; 8: e00982 GeM. ZhangY. HaoQ. ZhaoY. DongB. Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta-analysis Brain Behav. 2018 8 e00982 10.1002/brb3.982604370129877067 Search in Google Scholar

[30] George T.P.: Nicotinic receptor mechanisms in neuropsychiatric disorders: Therapeutic implications. Prim. Psychiatry, 2010; 17: 35–41 GeorgeT.P. Nicotinic receptor mechanisms in neuropsychiatric disorders: Therapeutic implications Prim. Psychiatry 2010 17 35 41 Search in Google Scholar

[31] Ghosh A.K., Cárdenas E.L., Osswald H.L.: The design, development, and evaluation of BACE1 inhibitors for the treatment of Alzheimer’s disease. W: Alzheimer’s Disease II. Topics in Medicinal Chemistry, vol 24, red.: M. Wolfe. Springer International Publishing, Cham 2016, 27–85 GhoshA.K. CárdenasE.L. OsswaldH.L. The design, development, and evaluation of BACE1 inhibitors for the treatment of Alzheimer’s disease W: Alzheimer’s Disease II. Topics in Medicinal Chemistry 24 red.: WolfeM. Springer International Publishing Cham 2016 27 85 10.1007/7355_2016_16 Search in Google Scholar

[32] Godyń J., Jończyk J., Panek D., Malawska B.: Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol. Rep., 2016; 68: 127–138 GodyńJ. JończykJ. PanekD. MalawskaB. Therapeutic strategies for Alzheimer’s disease in clinical trials Pharmacol. Rep. 2016 68 127 138 10.1016/j.pharep.2015.07.00626721364 Search in Google Scholar

[33] Gratuze M., Leyns C.E.G., Holtzman D.M.: New insights into the role of TREM2 in Alzheimer’s disease. Mol. Neurodegener., 2018; 13: 66 GratuzeM. LeynsC.E.G. HoltzmanD.M. New insights into the role of TREM2 in Alzheimer’s disease Mol. Neurodegener. 2018 13 66 10.1186/s13024-018-0298-9630250030572908 Search in Google Scholar

[34] Hampel H., Mesulam M.M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., Khachaturian Z.S.: The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 2018; 141: 1917–1933 HampelH. MesulamM.M. CuelloA.C. FarlowM.R. GiacobiniE. GrossbergG.T. KhachaturianA.S. VergalloA. CavedoE. SnyderP.J. KhachaturianZ.S. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease Brain 2018 141 1917 1933 10.1093/brain/awy132602263229850777 Search in Google Scholar

[35] Hull M., Sadowsky C., Arai H., Le Prince Leterme G., Holstein A., Booth K., Peng Y., Yoshiyama T., Suzuki H., Ketter N., Liu E., Ryan J.M.: Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer’s disease. Curr. Alzheimer Res., 2017; 14: 696–708 HullM. SadowskyC. AraiH. Le Prince LetermeG. HolsteinA. BoothK. PengY. YoshiyamaT. SuzukiH. KetterN. LiuE. RyanJ.M. Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer’s disease Curr. Alzheimer Res. 2017 14 696 708 10.2174/1567205014666170117101537554356728124589 Search in Google Scholar

[36] Hung S.Y., Fu W.M.: Drug candidates in clinical trials for Alzheimer’s disease. J. Biomed. Sci., 2017; 24: 47 HungS.Y. FuW.M. Drug candidates in clinical trials for Alzheimer’s disease J. Biomed. Sci. 2017 24 47 10.1186/s12929-017-0355-7551635028720101 Search in Google Scholar

[37] Jadhav S., Avila J., Schöll M., Kovacs G.G., Kövari E., Skrabana R., Evans L.D., Kontsekova E., Malawska B., de Silva R., Buee L., Zilka N.: A walk through tau therapeutic strategies. Acta Neuropathol. Commun., 2019; 7: 22 JadhavS. AvilaJ. SchöllM. KovacsG.G. KövariE. SkrabanaR. EvansL.D. KontsekovaE. MalawskaB. de SilvaR. BueeL. ZilkaN. A walk through tau therapeutic strategies Acta Neuropathol. Commun. 2019 7 22 10.1186/s40478-019-0664-z637669230767766 Search in Google Scholar

[38] Kowalski K., Mulak A.: Brain-gut-microbiota axis in Alzheimer’s disease. J. Neurogastroenterol. Motil., 2019; 25: 48–60 KowalskiK. MulakA. Brain-gut-microbiota axis in Alzheimer’s disease J. Neurogastroenterol. Motil. 2019 25 48 60 10.5056/jnm18087632620930646475 Search in Google Scholar

[39] Krstic D., Knuesel I.: Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol., 2013; 9: 25–34 KrsticD. KnueselI. Deciphering the mechanism underlying late-onset Alzheimer disease Nat. Rev. Neurol. 2013 9 25 34 10.1038/nrneurol.2012.23623183882 Search in Google Scholar

[40] Lacosta A.M., Pascual-Lucas M., Pesini P., Casabona D., Pérez-Grijalba V., Marcos-Campos I., Sarasa L., Canudas J., Badi H., Monleón I., San-José I., Munuera J., Rodríguez-Gómez O., Abdelnour C., Lafuente A. i wsp.: Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res. Ther., 2018; 10: 12 LacostaA.M. Pascual-LucasM. PesiniP. CasabonaD. Pérez-GrijalbaV. Marcos-CamposI. SarasaL. CanudasJ. BadiH. MonleónI. San-JoséI. MunueraJ. Rodríguez-GómezO. AbdelnourC. LafuenteA. Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase I trial Alzheimers Res. Ther. 2018 10 12 10.1186/s13195-018-0340-8578964429378651 Search in Google Scholar

[41] Lee J.K., Kim N.J.: Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules, 2017; 22: 1287–1310 LeeJ.K. KimN.J. Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease Molecules 2017 22 1287 1310 10.3390/molecules22081287615207628767069 Search in Google Scholar

[42] Lopez Lopez C., Caputo A., Liu F., Riviere M.E., Rouzade-Dominguez M.L., Thomas R.G., Langbaum J.B., Lenz R., Reiman E.M., Graf A., Tariot P.N.: The Alzheimer’s Prevention Initiative Generation Program: Evaluating CNP520 efficacy in the prevention of Alzheimer’s disease. J. Prev. Alzheimers Dis., 2017; 4: 242–246 Lopez LopezC. CaputoA. LiuF. RiviereM.E. Rouzade-DominguezM.L. ThomasR.G. LangbaumJ.B. LenzR. ReimanE.M. GrafA. TariotP.N. The Alzheimer’s Prevention Initiative Generation Program: Evaluating CNP520 efficacy in the prevention of Alzheimer’s disease J. Prev. Alzheimers Dis. 2017 4 242 246 10.14283/jpad.2017.3729181489 Search in Google Scholar

[43] Maia M.A., Sousa E.: BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals, 2019; 12: E41 MaiaM.A. SousaE. BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease Pharmaceuticals 2019 12 E41 10.3390/ph12010041646919730893882 Search in Google Scholar

[44] Marszałek M.: Choroba Alzheimera a produkty degradacji białka APP. Formowanie i różnorodność form fibrylujących peptydów – wybrane aspekty. Postępy Hig. Med. Dośw., 2016; 70: 787–796 MarszałekM. Choroba Alzheimera a produkty degradacji białka APP. Formowanie i różnorodność form fibrylujących peptydów – wybrane aspekty Postępy Hig. Med. Dośw. 2016 70 787 796 10.5604/17322693.120921027383575 Search in Google Scholar

[45] Marszałek M.: Cukrzyca typu 2 a choroba Alzheimera – jedna czy dwie choroby? Mechanizmy asocjacji. Postępy Hig. Med. Dośw., 2013; 67: 653–671 MarszałekM. Cukrzyca typu 2 a choroba Alzheimera – jedna czy dwie choroby? Mechanizmy asocjacji. Postępy Hig. Med. Dośw. 2013 67 653 671 10.5604/17322693.105954924018430 Search in Google Scholar

[46] Medina M.: An overview on the clinical development of tau-based therapeutics. Int. J. Mol. Sci., 2018; 19: 1160 MedinaM. An overview on the clinical development of tau-based therapeutics Int. J. Mol. Sci. 2018 19 1160 10.3390/ijms19041160597930029641484 Search in Google Scholar

[47] Novak P., Schmidt R., Kontsekova E., Kovacech B., Smolek T., Katina S., Fialova L., Prcina M., Parrak V., Dal-Bianco P., Brunner M., Staffen W., Rainer M., Ondrus M., Ropele S. i wsp.: FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res. Ther., 2018; 10: 108 NovakP. SchmidtR. KontsekovaE. KovacechB. SmolekT. KatinaS. FialovaL. PrcinaM. ParrakV. Dal-BiancoP. BrunnerM. StaffenW. RainerM. OndrusM. RopeleS. FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease Alzheimers Res. Ther. 2018 10 108 10.1186/s13195-018-0436-1620158630355322 Search in Google Scholar

[48] Okamoto M., Gray J.D., Larson C.S., Kazim S.F., Soya H., McEwen B.S., Pereira A.C.: Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer’s disease. Transl. Psychiatry, 2018; 8: 153 OkamotoM. GrayJ.D. LarsonC.S. KazimS.F. SoyaH. McEwenB.S. PereiraA.C. Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer’s disease Transl. Psychiatry 2018 8 153 10.1038/s41398-018-0201-z609242630108205 Search in Google Scholar

[49] Panza F., Lozupone M., Watling M., Imbimbo B.P.: Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev. Neurother., 2019; 19: 599–602 PanzaF. LozuponeM. WatlingM. ImbimboB.P. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev. Neurother. 2019 19 599 602 10.1080/14737175.2019.162175131112433 Search in Google Scholar

[50] Pasinetti G.M., Wang J., Ho L., Zhao W., Dubner L.: Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim. Biophys. Acta, 2015; 1852: 1202–1208 PasinettiG.M. WangJ. HoL. ZhaoW. DubnerL. Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment Biochim. Biophys. Acta 2015 1852 1202 1208 10.1016/j.bbadis.2014.10.006438083225315300 Search in Google Scholar

[51] Payesko J.: GRF6019 Shows Positive Phase 2 Results in Mild to Moderate Alzheimer Disease. https://www.neurologylive.com/clinical-focus/grf6019-shows-positive-phase-2-results-in-mild-to-moderate-alzheimer-disease (03.03.2020) PayeskoJ. GRF6019 Shows Positive Phase 2 Results in Mild to Moderate Alzheimer Disease https://www.neurologylive.com/clinical-focus/grf6019-shows-positive-phase-2-results-in-mild-to-moderate-alzheimer-disease (03.03.2020) Search in Google Scholar

[52] Petrov A.M., Lam M., Mast N., Moon J., Li Y., Maxfield E., Pikuleva I.A.: CYP46A1 Activation by efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice. Neurotherapeutics, 2019; 16: 710–724 PetrovA.M. LamM. MastN. MoonJ. LiY. MaxfieldE. PikulevaI.A. CYP46A1 Activation by efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice Neurotherapeutics 2019 16 710 724 10.1007/s13311-019-00737-0 Search in Google Scholar

[53] Safieh M., Korczyn A.D., Michaelson D.M.: ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med., 2019; 17: 64 SafiehM. KorczynA.D. MichaelsonD.M. ApoE4: An emerging therapeutic target for Alzheimer’s disease BMC Med. 2019 17 64 10.1186/s12916-019-1299-4 Search in Google Scholar

[54] Sanabria-Castro A., Alvarado-Echeverría I., Monge-Bonilla C.: Molecular pathogenesis of Alzheimer’s disease: An update. Ann. Neurosci., 2017; 24: 46–54 Sanabria-CastroA. Alvarado-EcheverríaI. Monge-BonillaC. Molecular pathogenesis of Alzheimer’s disease: An update Ann. Neurosci. 2017 24 46 54 10.1159/000464422 Search in Google Scholar

[55] Shaikh S., Rizvi S.M., Shakil S., Riyaz S., Biswas D., Jahan R.: Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol. Appl. Biochem., 2016; 63: 145–150 ShaikhS. RizviS.M. ShakilS. RiyazS. BiswasD. JahanR. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders Biotechnol. Appl. Biochem. 2016 63 145 150 10.1002/bab.1319 Search in Google Scholar

[56] Siopi E., Llufriu-Dabén G., Cho A.H., Vidal-Lletjós S., Plotkine M., Marchand-Leroux C., Jafarian-Tehrani M.: Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuro-protection following traumatic brain injury in mice. Neuropharmacology, 2013; 67: 183–192 SiopiE. Llufriu-DabénG. ChoA.H. Vidal-LletjósS. PlotkineM. Marchand-LerouxC. Jafarian-TehraniM. Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuro-protection following traumatic brain injury in mice Neuropharmacology 2013 67 183 192 10.1016/j.neuropharm.2012.11.009 Search in Google Scholar

[57] Smith A.: Positive results for UB-311 Alzheimer’s vaccine. http://www.pharmatimes.com/news/positive_results_for_ub-311_alzheimers_vaccine_1275579 (03.03.2020) SmithA. Positive results for UB-311 Alzheimer’s vaccine http://www.pharmatimes.com/news/positive_results_for_ub-311_alzheimers_vaccine_1275579 (03.03.2020) Search in Google Scholar

[58] Solanezumab. https://www.alzforum.org/therapeutics/solanezumab (03.03.2020) Solanezumab https://www.alzforum.org/therapeutics/solanezumab (03.03.2020) Search in Google Scholar

[59] The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials: Material Science or Marketing?. https://www.trialsitenews.com/the-new-chinese-alzheimers-drug-gv-971-making-its-way-to-global-trials-material-science-or-marketing/ (25.05.2020) The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials Material Science or Marketing? https://www.trialsitenews.com/the-new-chinese-alzheimers-drug-gv-971-making-its-way-to-global-trials-material-science-or-marketing/ (25.05.2020) Search in Google Scholar

[60] TPI 287. https://www.alzforum.org/therapeutics/tpi-287 (03.03.2020) TPI 287 https://www.alzforum.org/therapeutics/tpi-287 (03.03.2020) Search in Google Scholar

[61] Traneurocin Phase 2A Trial Results Show Improvements for People With Mild Cognitive Impairment. https://practicalneurology.com/index.php/news/traneurocin-phase-2a-trial-results-show-improvements-for-people-with-mild-cognitive-impairment (03.03.2020) Traneurocin Phase 2A Trial Results Show Improvements for People With Mild Cognitive Impairment https://practicalneurology.com/index.php/news/traneurocin-phase-2a-trial-results-show-improvements-for-people-with-mild-cognitive-impairment (03.03.2020) Search in Google Scholar

[62] Umibecestat. https://www.alzforum.org/therapeutics/umibecestat (03.03.2020) Umibecestat https://www.alzforum.org/therapeutics/umibecestat (03.03.2020) Search in Google Scholar

[63] Vellas B., Coley N., Ousset P.J., Berrut G., Dartigues J.F., Dubois B., Grandjean H., Pasquier F., Piette F., Robert P., Touchon J., Garnier P., Mathiex-Fortunet H., Andrieu S., GuidAge Study Group: Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): A randomised placebo-controlled trial. Lancet Neurol., 2012; 11: 851–859 VellasB. ColeyN. OussetP.J. BerrutG. DartiguesJ.F. DuboisB. GrandjeanH. PasquierF. PietteF. RobertP. TouchonJ. GarnierP. Mathiex-FortunetH. AndrieuS. GuidAge Study Group Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): A randomised placebo-controlled trial Lancet Neurol. 2012 11 851 859 10.1016/S1474-4422(12)70206-5 Search in Google Scholar

[64] Verma S., Kumar A., Tripathi T., Kumar A.: Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer’s disease therapy. J. Pharm. Pharmacol., 2018; 70: 985–993 VermaS. KumarA. TripathiT. KumarA. Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer’s disease therapy J. Pharm. Pharmacol. 2018 70 985 993 10.1111/jphp.1291929663387 Search in Google Scholar

[65] Wang X., Sun G., Feng T., Zhang J., Huang X., Wang T., Xie Z., Chu X., Yang J., Wang H., Chang S., Gong Y., Ruan L., Zhang G., Yan S. i wsp.: Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res., 2019; 29: 787–803 WangX. SunG. FengT. ZhangJ. HuangX. WangT. XieZ. ChuX. YangJ. WangH. ChangS. GongY. RuanL. ZhangG. YanS. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression Cell Res. 2019 29 787 803 10.1038/s41422-019-0216-x679685431488882 Search in Google Scholar

[66] Wisniewski T., Drummond E.: Developing therapeutic vaccines against Alzheimer’s disease. Expert Rev. Vaccines, 2016; 15: 401–415 WisniewskiT. DrummondE. Developing therapeutic vaccines against Alzheimer’s disease Expert Rev. Vaccines 2016 15 401 415 10.1586/14760584.2016.1121815494085826577574 Search in Google Scholar

[67] Wojsiat J., Zoltowska K.M., Laskowska-Kaszub K., Wojda U.: Oxidant/antioxidant imbalance in Alzheimer’s disease: Therapeutic and diagnostic prospects. Oxid. Med. Cell. Longev., 2018; 2018: 6435861 WojsiatJ. ZoltowskaK.M. Laskowska-KaszubK. WojdaU. Oxidant/antioxidant imbalance in Alzheimer’s disease: Therapeutic and diagnostic prospects Oxid. Med. Cell. Longev. 2018 2018 6435861 10.1155/2018/6435861583177129636850 Search in Google Scholar

[68] Xicota L., Rodriguez-Morato J., Dierssen M., de la Torre R.: Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease. Curr. Drug Targets, 2017; 18: 174–195 XicotaL. Rodriguez-MoratoJ. DierssenM. de la TorreR. Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease Curr. Drug Targets 2017 18 174 195 10.2174/138945011666615082511365526302801 Search in Google Scholar

[69] Zhang C., Griciuc A., Hudry E., Wan Y., Quinti L., Ward J., Forte A.M., Shen X., Ran C., Elmaleh D.R., Tanzi R.E.: Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci. Rep., 2018; 8: 1144 ZhangC. GriciucA. HudryE. WanY. QuintiL. WardJ. ForteA.M. ShenX. RanC. ElmalehD.R. TanziR.E. Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis Sci. Rep. 2018 8 1144 10.1038/s41598-018-19641-2577354529348604 Search in Google Scholar

[70] Zhang Y., Li P., Feng J., Wu M.: Dysfunction of NMDA receptors in Alzheimer’s disease. Neurol. Sci., 2016; 37: 1039–1047 ZhangY. LiP. FengJ. WuM. Dysfunction of NMDA receptors in Alzheimer’s disease Neurol. Sci. 2016 37 1039 1047 10.1007/s10072-016-2546-5491757426971324 Search in Google Scholar

[71] Zhao Y., Zhao B.: Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid. Med. Cell. Longev., 2013; 2013: 316523 ZhaoY. ZhaoB. Oxidative stress and the pathogenesis of Alzheimer’s disease Oxid. Med. Cell. Longev. 2013 2013 316523 10.1155/2013/316523374598123983897 Search in Google Scholar